title: [ACE inhibitors continue to be first choice in the treatment of heart failure patients].
abstract: A new Cochrane metaanalysis has reviewed the literature on the use of angiotensin receptor blockers (ARB) in patients with heart failure and left ventricular systolic dysfunction. The conclusion supports the present recommendation from the European Society of Cardiology that angiotensin converting enzyme inhibitors (ACE-I) are first choice and that ARBs should be reserved to patients who are intolerant to ACE-Is. Neither ACE-Is nor ARBs are effective in the treatment of heart failure patients with normal left ventricular function.
authors.affiliation: Medicinsk Afdeling, Køge Sygehus, Lykkebækvej 1, 4600 Køge, Denmark. nga@regionsjaelland.dk
authors.forename: Niels
authors.initials: N
authors.lastname: Gadsbøll
authors.forename: Christian Torp
authors.initials: CT
authors.lastname: Pedersen
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D012196:Review Literature as Topic; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors